Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.
Saved in:
| Title: | Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis. |
|---|---|
| Authors: | Miller TM; Department of Neurology, Neuromuscular Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri., Cudkowicz ME; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston., Shaw PJ; Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, United Kingdom.; National Institute for Health and Care Research Sheffield Biomedical Research Centre and Clinical Research Facility, University of Sheffield and Sheffield Teaching Hospitals National Health Service Foundation Trust, Sheffield, United Kingdom., Genge A; Department of Neurology and Neurosurgery, Faculty of Medicine and Health Sciences, McGill University, Montreal, Quebec, Canada., Sobue G; Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.; Aichi Medical University, Aichi, Japan., Bucelli RC; Department of Neurology, Neuromuscular Medicine, Washington University School of Medicine in St Louis, St Louis, Missouri., Chiò A; Rita Levi Montalcini Department of Neurosciences, University of Turin, Turin, Italy., Van Damme P; University Hospitals Leuven, Leuven, Belgium.; Neuroscience Department, Leuven Brain Institute, KU Leuven, Leuven, Belgium., Ludolph AC; Department of Neurology, University of Ulm, Ulm, Germany., Glass JD; Emory University School of Medicine, Atlanta, Georgia., Andrews JA; Department of Neurology, NYU Langone, New York, New York., Babu S; Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston., Benatar M; Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida.; Amyotrophic Lateral Sclerosis Center, University of Miami Miller School of Medicine, Miami, Florida., McDermott CJ; Division of Neuroscience, School of Medicine and Population Health, University of Sheffield, Sheffield, United Kingdom., Salachas F; Paris Amyotrophic Lateral Sclerosis Center, Department of Neurology, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France., Bruneteau G; Paris Amyotrophic Lateral Sclerosis Center, Department of Neurology, Pitié-Salpêtrière Hospital, Assistance Publique Hôpitaux de Paris, Paris, France., Al-Chalabi A; Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.; Department of Neurology, King's College Hospital, London, United Kingdom., Amorin M; Biogen, Cambridge, Massachusetts., Nestorov I; Biogen, Cambridge, Massachusetts., Graham D; Biogen, Cambridge, Massachusetts., Lin L; Biogen, Cambridge, Massachusetts., Sun P; Biogen, Cambridge, Massachusetts., McNeill M; Biogen, Maidenhead, United Kingdom., Malek S; Biogen, Cambridge, Massachusetts., Inra J; Biogen, Cambridge, Massachusetts., Garafalo S; Biogen, Cambridge, Massachusetts., Fradette S; Biogen, Cambridge, Massachusetts. |
| Corporate Authors: | VALOR and OLE Working Group |
| Source: | JAMA neurology [JAMA Neurol] 2026 Feb 01; Vol. 83 (2), pp. 115-125. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589536 Publication Model: Print Cited Medium: Internet ISSN: 2168-6157 (Electronic) Linking ISSN: 21686149 NLM ISO Abbreviation: JAMA Neurol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6157 |
|---|---|
| DOI: | 10.1001/jamaneurol.2025.4946 |
